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Background: In breast cancer, the role of epigenetic alterations including modifications of the acetylation status of
histones in carcinogenesis has been an important research focus during the last years. An increased deacetylation
of histones leads to increased cell proliferation, cell migration, angiogenesis and invasion. Class 1 histone
deacetylases (HDAC) seem to be most important during carcinogenesis.
Methods: The immunhistochemical expression of HDAC1, 2 and 3 was analyzed on tissue microarrays (TMAs) from
238 patients with primary breast cancer. We analyzed the nuclear staining intensity (negative, weak, moderate,
strong) as well as the percentage of positive tumor cells and calculated the immunoreactivity score (0–12).
Expression was correlated with clinicopathological parameters and patient survival.
Results: In this cohort, we found a differential positive expression of HDAC1, HDAC2 and HDAC3. HDAC2 and
HDAC3 expression was significantly higher in less differentiated tumors: HDAC2 (n=207), p<0.001 and HDAC3
(n=220), p<0.001 and correlated with negative hormone receptor status: HDAC2 (n=206), p=0.02 and HDAC3
(n=219), p=0.04. Additionally, a high HDAC2 expression was significantly associated with an overexpression of HER2
(n=203, p=0.005) and the presence of nodal metastasis (n=200, p=0.04).
HDAC1 was highly expressed in hormone receptor positive tumors (n=203; p<0.001).
Conclusion: As a conclusion, our results show that the class-1 HDAC isoenzymes 1, 2 and 3 are differentially
expressed in breast cancer. HDAC2 and HDAC3 are strongly expressed in subgroups of tumor with features of a
more aggressive tumor type.
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Table 1 Patient characteristics
Characteristic No. of patients %
All cases 238 100
Histological type
Ductal carcinoma 173 72.7
Lobular carcinoma 39 16.4














both negative 45 19.3
ESR1 and/or Progesterone positive 188 80.7
HER-2 status*
negative (score 0, 1+ and 2+ SISH negative) 202 88.6
positive (score 2+ SISH positive and score 3+) 26 11.4
age
<= 60 years 121 50.8
> 60 years 117 49.2
* = Not all of the data were available for all patients.
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Despite latest individualized therapies, breast cancer is
still with 14% of all estimated deaths in the United States
the second leading cause of cancer related death in
woman in 2012. To date, breast cancer is the most fre-
quently diagnosed cancer in females with over 226.000
new cases [1].
During the last years, several studies about the role of
epigenetic alterations including modifications of the
acetylation status of histones in the development of hu-
man cancer have been published [2,3]. An increased
deacetylation of histones leads to an increased cell pro-
liferation, cell migration, angiogenesis and invasion by
reducing the transcription of tumorsuppressor genes [4].
Until now, eighteen different isoenzymes of histone
deacetylases (HDACs) are known which are divided into
four subclasses. With respect to carcinogenesis, class 1
HDACs (HDAC1,2,3 and 8) seem to be the most im-
portant ones. HDAC1, 2 and 3 are expressed in the nu-
cleus of normal cells and shows, in contrary to the other
classes, an ubiquitous expression [5,6]. In the last years,
the expression of HDACs and its prognostic value has
been analyzed in different kinds of human cancers [7-9].
The prognostic role of class 1 HDACs seems to be dif-
ferent in various kinds of tumor entities [6]. Among the
HDAC inhibitors, which can be categorized based on
their structure, suberoylanilide hydroxamic acid (SAHA)
was first approved for therapy for cutaneous T-cell
lymphoma in 2006 [10].
The majority (70-80%) of breast cancer shows an over-
expression of estrogen receptor alpha (ESR1). The endo-
crine therapy with first anti-estrogens or later aromatase
inhibitors was one of the first targeted therapies in
breast cancer, but not all of the patients with hormone
receptor (estrogen and/or progesterone) positive tumors
have a significant benefit due to the development of
“endocrine resistance disease” [11]. In this context, a re-
duced activity of CYP2D6 was discussed, too [12]. The
transcriptional regulation of ESR1 is influenced by mul-
tiple promoters, and acetylation was found to be one of
the key mediators for transcription [13]. Recently, some
authors described the effect of the addition of HDAC-
inhibitors to restore the efficiency of endocrine therapy
[3,14,15], for example through re-expression of ESR1
mRNA by trichostatin A or Valproate in ESR1 negative
breast cancer cells [16,17]. Regarding the human epider-
mal growth receptor 2 (HER2), in vitro studies showed
an increased degradation of HER2 after application of
SAHA [18].
In this study, we analyzed the expression of the
isoforms HDAC1-3 using immunohistochemical analysis
on tissue microarrays (TMAs) and correlated them with
relevant clinicopathological parameters, especially with
hormone receptor status. Furthermore, we examined apotential prognostic impact of the expression of these
proteins.
Methods
Study population and histopathological examination
For construction of tissue microarrays, we used formalin-
fixed paraffin embedded (FFPE) tissue samples from 238
patients with primary invasive breast cancer. The overall
survival was defined as the time between first diagnosis
and date of death. Most of the clinicopathological data in-
cluding histolocigal type, tumor size and nodal status were
extracted from the pathology reports. Some parameters
(grade, hormone receptor status, HER2-status) were eval-
uated on whole slides respectively on TMAs. The detailed
patient characteristics are shown in Table 1.
The immunhistochemical evaluation was done by a
pathologist (A.K., assisted by L.J.). According to previous
analyses [6] we analyzed the nuclear intensity of HDAC
expression (negative, weak, moderate, strong) as well as
the percentage of positive tumor cells and calculated the
immunoreactivity score (IRS, 0–12) by multiplication of













HDAC 1 34.1 33.2 32.7
HDAC 2 43.4 32.5 24.1
HDAC 3 35.7 32.6 31.7
Figure 1 Immunhistochemical expression of HDAC2. Low (1a) expression of HDAC2 in invasive breast cancer, in this sample, only a few
tumor cells (≤ 20%) show a weak HDAC2 expression (IRS 2; magnification power 400). Figure 1a shows the predominant negative expression.
High (1b) expression of HDAC2 in invasive breast cancer, most of the tumor cells (≤ 70%) show a strong expression of HDAC2 (IRS 9;
magnification power 400). The inset shows a negative expression of HDAC2 in a palatine tonsil that serves as an internal negative control
(magnification power 400).
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212 for HDAC2 and 224 samples for HDAC3 with ex-
pression data could be included in the final analysis.
This biomarker study has been approved by the Charité
University Ethics Committee (reference number EA1/
139/05).
Immunohistochemical staining
Immunohistochemical stainings were done according to
standard procedures as previously described [6,9]. The
following antibodies and dilutions were used: polyclonal
rabbit anti-HDAC1 antibody (Abcam, Cambridge, UK;
dilution: 1:11), monoclonal mouse anti-HDAC2 (Abcam,
Cambridge, UK; dilution: 1:5.000), monoclonal mouse
anti-HDAC3 (BD Biosience, Franklin Lakes, USA; dilu-
tion: 1:500). The specifity of the antibodies was de-
scribed in previous studies [19]. After deparaffinization,
the slides were boiled for 5 minutes in a pressure cooker
in 0.01 M sodium citrate buffer (pH 6.0). Before incuba-
tion with the primary antibody at 4°C overnight, the
slides were washed with TBS and blocked with blocking
reagent for 5 to 10 minutes (Dako, Glostrup, Denmark).
Subsequently, the slides were washed in TBS/Tween and
the incubation with the second antibody using a
streptavidin-biotin system (BioGene, San Roman, CA,
USA) followed for 20 minutes at room temperature. A fast
red system was used for colour developing (Sigma-Aldrich
Chemie, Steinheim, Germany). At the end, the stained
slides were covered with Aquatex (Merck, Darmstadt,
Germany).
Statistical evaluation
The HDAC expression was divided into three IRS
groups: low (IRS 0–4), intermediate (IRS 6–8) and high
(IRS 9 – 12). For statistical analysis, SPSS Statistics Ver-
sion 18 (IBM, Armonk, USA) was used. P-values smallerthan 0.05 were regarded as significant. χ2-test for trends
was used for linear correlations. Survival analyses were
created using Kaplan-Meier-method and log-rank test.
Results
Expression of HDACs in breast cancer
We could find a differential expression of HDAC1,
HDAC2 and HDAC3 in this cohort. Most of the tumors
showed an intermediate or high expression of the analysed
isoenzymes. Figure 1 exemplarily depicts a breast carcin-
oma with a low (Figure 1a) and a high (Figure 1b) expres-
sion of HDAC2.
In breast cancer, high (IRS 9–12) nuclear expression of
HDAC1, HDAC2 and HDAC3 was observed in 32.7%,
24.1% and 31.7% of cases, respectively. Low expression
(IRS 0–4) of the three isoforms was found in 34.1%,
43.4% and 35.7%, whereas an intermediate expression of
HDAC1, HDAC2 and HDAC3 could be seen in 33.2%,
32.5% and 32.6% of cases (Table 2).
Correlation of HDAC isoforms with clinicopathological
parameters
We observed significant correlations between the HDAC
isoenzymes and several clinicopathological parameters.
HDAC1 was expressed higher in hormone receptor
positive tumors (38.3%) vs. hormone receptor negative
tumors (9.7%). Most of the hormone receptor negative
Table 3 Association of HDAC1 expression with various clinicopathological factors








All cases 208 (100%) 71 (34.1%) 69 (33.2%) 68 (32.7%) –
Histological type 0.17
Ductal carcinoma/Other 176 (100%) 62 (35.2%) 60 (34.1%) 54 (30.7%)
Lobular carcinoma 28 (100%) 7 (25%) 9 (32.1%) 12 (42.9%)
Histological grade 0.89
G1 61 (100%) 24 (39.3%) 20 (32.8%) 17 (27.9%)
G2 90 (100%) 25 (27.8%) 28 (31.1%) 37 (41.1%)
G3 53 (100%) 20 (37.8%) 21 (39.6%) 12 (22.6%)
Nodal status 0.23
negative 129 (100%) 48 (37.2%) 42 (32.6%) 39 (30.2%)
positive 67 (100%) 18 (26.9%) 26 (38.8%) 23 (34.3%)
pT-Stage 0.88
pT1 116 (100%) 41 (35.3%) 37 (31.9%) 38 (32.8%)
pT2/pT3 78 (100%) 23 (29.5%) 30 (38.5%) 25 (32%)
pT4 9 (100%) 4 (44.4%) 2 (22.2%) 3 (33.4%)
Hormone receptor status <0.001*
Hormone receptor positive 162 (100%) 46 (28.4%) 54 (33.3%) 62 (38.3%)
Hormone receptor negative 41 (100%) 22 (53.7%) 15 (36.6%) 4 (9.7%)
HER2 status 0.71
negative 175 (100%) 60 (34.3%) 58 (33.1%) 57 (32.6%)
positive 25 (100%) 9 (36%) 9 (36%) 7 (28%)
Müller et al. BMC Cancer 2013, 13:215 Page 4 of 8
http://www.biomedcentral.com/1471-2407/13/215cancers (53.7%) showed a low HDAC1 expression
(p<0.001).
HDAC2 expression was correlated significantly with
histological grade: 43.6% of the grade 3 tumors exhibited
a high expression vs. 22.8% and 10% for grade 2 and
grade 1 tumors, respectively (p<0.001). In contrast,
56.7% of the grade 1 tumors showed a low expression.
Additionally, a high HDAC2 expression was significantly
associated with a negative hormone receptor status
(p=0.02) and an overexpression of HER2 (p=0.005) as
well as the presence of nodal metastasis (p=0.04).
A high HDAC3 expression was observed in less differ-
entiated (grade 3) tumors (p<0.001) and tumors with
negative hormone receptor status (p=0.04). The
remaining clinicopathological parameters revealed no
significant correlations. The correlations of all three iso-
enzymes are shown in Tables 3, 4 and 5.
HDAC2 and HDAC3 show a strong positive correl-
ation (p<0.001).
Correlation of HDAC isoforms with survival
The known prognostic factors including nodal status
(p<0.001), histopathological grading (p=0.009) and pT
status (p<0.001) achieved statistical significance in this
cohort. In contrast, none of the HDAC isoforms reached
significant prognostic relevance in our study using
Kaplan-Meyer survival analysis (Figure 2). Additionally,a co-expression of HDAC2 and HDAC3 did also not
reach significant prognostic relevance (data not shown).
Discussion
Our study demonstrates a differential expression of
HDAC1, HDAC2 and HDAC3 using immunohistochem-
istry in breast cancer. Expression of all three isoforms re-
vealed significant correlations with clinicopathological
parameters. Expression of HDAC2 and HDAC3 was sig-
nificantly higher in less differentiated tumors as well as in
tumors with negative hormone receptor status. Addition-
ally, tumors with HER2 overexpression and positive lymph
node metastasis showed a significant higher expression of
HDAC2. In contrast, a high expression of the HDAC1 was
found in hormone receptor positive tumors.
To our knowledge, this is the first time that the class-
1 isoforms HDAC1, -2 and −3 were analyzed together in
the same breast cancer cohort.
Krusche et al. [20] did an immunhistochemical ana-
lysis of the expression of HDAC1 and HDAC3 in 200
breast cancer samples. Similar to our findings, they
found a significant correlation between positive HDAC1
expression and positive hormone receptor expression. In
contrast to our results, they additionally described a cor-
relation of HDAC3 with a positive hormone receptor ex-
pression. They found no significant results concerning
the correlation of HDAC and grading.
Table 4 Association of HDAC2 expression with various clinicopathological factors








All cases 212 (100%) 92 (43.4%) 69 (32.5%) 51 (24.1%) –
Histological type 0.59
Ductal carcinoma/Other 180 (100%) 80 (44.4%) 56 (31.1%) 44 (24.5%)
Lobular carcinoma 27 (100%) 10 (37%) 10 (37%) 7 (26%)
Histological grade <0.001*
G1 60 (100%) 34 (56.7%) 20 (33.3%) 6 (10%)
G2 92 (100%) 39 (42.4%) 32 (34.8%) 21 (22.8%)
G3 55 (100%) 17 (30.9%) 14 (25.5%) 24 (43.6%)
Nodal status 0.04*
negative 130 (100%) 66 (50.8%) 36 (27.7%) 28 (21.5%)
positive 70 (100%) 23 (32.9%) 28 (40%) 19 (27.1%)
pT-Stage 0.43
pT1 117 (100%) 52 (44.4%) 41 (35%) 24 (20.6%)
pT2/pT3 79 (100%) 32 (40.5%) 22 (27.9%) 25 (31.6%)
pT4 10 (100%) 5 (50%) 3 (30%) 2 (20%)
Hormone receptor status 0.02*
Hormone receptor positive 163 (100%) 73 (44.8%) 59 (36.2%) 31 (19%)
Hormone receptor negative 43 (100%) 17 (39.5%) 7 (16.3%) 19 (44.2%)
HER2 status 0.005*
negative 178 (100%) 83 (46.6%) 55 (30.9%) 40 (22.5%)
positive 25 (100%) 5 (20%) 9 (36%) 11 (44%)
Table 5 Association of HDAC3 expression with various clinicopathological factors








All cases 224 (100%) 80 (35.7%) 73 (32.6%) 71 (31.6%) –
Histological type 0.34
Ductal carcinoma/Other 185 (100%) 69 (37.2%) 58 (31.4%) 58 (31.4%)
Lobular carcinoma 35 (100%) 10 (28.6%) 12 (34.3%) 13 (37.1%)
Histological grade <0.001*
G1 63 (100%) 32 (50.8%) 19 (30.2%) 12 (19%)
G2 101 (100%) 33 (32.7%) 35 (34.6%) 33 (32.7%)
G3 56 (100%) 14 (25%) 16 (28.6%) 26 (46.4%)
Nodal status 0.61
negative 133 (100%) 51 (38.3%) 39 (29.3%) 43 (32.4%)
positive 78 (100%) 26 (33.3%) 26 (33.3%) 26 (33.3%)
pT-Stage 0.55
pT1 119 (100%) 43 (36.1%) 37 (31.1%) 39 (32.8%)
pT2/pT3 87 (100%) 28 (32.2%) 29 (33.3%) 30 (34.5%)
pT4 13 (100%) 7 (53.8%) 4 (30.8%) 2 (15.4%)
Hormone receptor status 0.04*
Hormone receptor positive 176 (100%) 65 (36.9%) 63 (35.8%) 48 (27.3%)
Hormone receptor negative 43 (100%) 14 (32.6%) 7 (16.3%) 22 (51.2%)
HER2 status 0.12
negative 191 (100%) 71 (37.2%) 63 (35.8%) 48 (27.3%)
positive 25 (100%) 8 (32%) 4 (16%) 13 (52%)
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Figure 2 Overall survival. Figure 2 shows the overall survival for the whole cohort. The nodal status (Figure 2a; p<0.001), the histological
grading (Figure 2b; p=0.009) as well as the pT status (Figure 2c; p<0.001) reached statistical significance. The expression of HDAC1 (Figure 2d;
p=0.557), HDAC 2 (Figure 2e; p=0.316) and HDAC 3 (Figure 2f; p=0.536) did not reach significant prognostic relevance regarding the
overall survival.
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lar results concerning HDAC1, with an increased
HDAC1 mRNA expression in hormone receptor positive
tumors [21].
Most interestingly, we could find a significantly higher
expression of HDAC2 and −3 in more aggressive tumor
types. Expression of HDAC2 and −3 was higher in
poorly differentiated and hormone receptor negative tu-
mors, for HDAC2 we also found a significant correlation
with HER2 overexpression. This correlation of HDACs
and clincopathological parameters, which mark a more
aggressive tumor type, was shown in other histological
cancer types before [6].
In accordance with our results other studies might
also suggest a suppression of estrogen receptor by
overexpression of HDAC. Several in vitro studies ana-
lyzed the reexpression of the estrogen receptor after
therapy with Trichostatin A [16]. Zhou et al. [22]
achieved a restoring of estrogen receptor mRNA and
protein expression. These findings suggest that estrogen
receptor could be suppressed by enhanced HDAC activ-
ity and restored by HDAC inhibitors.
Additionally, multiple groups have analyzed the influ-
ence of HDAC inhibitors in estrogen receptor positivebreast cancer. Here, treatment with HDAC inhibitors led
to a down-regulation of estrogen receptor alpha [23,24].
In contrast, the estrogen receptor beta was shown to in-
crease the antiproliferative potential of HDAC inhibitors
as well as apoptosis as analyzed by Duong et al. [25].
In clinical studies the combination of HDAC inhibitors
and hormone therapy showed first effects. Munster et al.
could show an response rate of 19% for the combination
of Vorinostat and Tamoxifen [26] In contrast, the mono-
therapy with Tamoxifen in metastatic breast cancer
achieved only a response rate below 10%.
Both, in vitro and in vivo studies show that HDAC2
could be a potential biomarker. Marchion et al. showed the
selective inhibition of HDAC2 in breast cancer cells to be
responsible for hyperacetylation of histones and proteins
[23]. In clinical studies tumors with HDAC2-expression
showed a more acetylated histone status after therapy with
Doxorubicin and Vorinostat [26]. HDAC2 might therefore
mark tumors with response to HDAC inhibitors.
In normal mammary gland, we saw a homogenous
expression of the HDAC class I isoenzymes. Similar
results are described by other groups [27].
Despite our long observation time (median: 158
months) we could not observe any prognostic influence
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retrospective analyses. This could be due to the influ-
ence of variable therapy regimens in this time as well as
the missing parameters of disease-specific deaths. Other
studies have described a prognostic role for HDAC1 in
breast cancer [20]. Due to the staining on a TMA, a
possible heterogeneously expression of the analysed iso-
enzymes could be underrepresented.
Altogether, the interaction between the hormone re-
ceptor status and the HDAC expression as well as
HDAC inhibitors are complex and need to be evaluated
in further studies [13].
Conclusions
As a conclusion, our results show that the class-1 HDAC
isoenzymes 1, 2 and 3 are differentially expressed in
breast cancer. HDAC2 and HDAC3 are strongly
expressed in more aggressive tumor subtypes.
Based on our results, we suggest that HDAC inhibitors
could be evaluated to restore the estrogen receptor in
breast cancer cells and the combination of HDAC inhib-
itors and hormone therapy could be successful. Based
on our results and those of other groups [10,23,28]
HDAC2 might be a potential biomarker and a selective
therapeutic target.
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